MetaCap

Palisade Bio (PALI) vs Protara Therapeutics (TARA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Palisade Bio (PALI) has outperformed Protara Therapeutics (TARA) over the past year, losing 60.6% versus a loss of 68.6%. Over five years, TARA leads with a -67.8% price change compared with -100.0% for PALI. Palisade Bio is the larger company by market cap ($150.7 million vs $140.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PALI-60.57%TARA-68.60%
+37%-20%-76%
Nov 21, 20251 yearNov 20, 2026
PALI-99.95%TARA-68.33%
+8%-49%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PALI versus TARA key metrics
MetricPALITARA
Share price$0.8399$2.28
Market cap$150.74M$140.38M
1-day change-9.24%-5.00%
YTD return-64.26%-57.22%
1-year return-60.57%-68.60%
5-year return-99.95%-67.80%
P/E ratio (TTM)0.91—
EPS (TTM)$0.92$-1.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-16.78M$-57.44M
52-week high$2.86$7.82
52-week low$0.8381$2.09
Distance from 52-week high-70.63%-70.84%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+935.84%+1010.96%
Average volume3.19M1.07M
Shares outstanding179.28M61.57M
Employees1446
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Palisade Bio

PALI stock →

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees

About Protara Therapeutics

TARA stock →

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees

PALI vs TARA FAQ

Which is bigger, Palisade Bio or Protara Therapeutics?

Palisade Bio (PALI) is larger, with a market capitalization of $150.74M compared with $140.38M for Protara Therapeutics (TARA).

Which stock has performed better over the past year, PALI or TARA?

PALI returned -60.57% over the past 12 months, compared with -68.60% for TARA (price return, excluding dividends). Past performance does not predict future results.

Are Palisade Bio and Protara Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons